Contrastingly, a meta-analysis of randomized controlled trials of the safety of TNF blockers in over 8,800 RA patients did not identify an increased risk of serious bacterial infection in the standard recommended dose. The gene discussed is TNF; the disease is rheumatoid arthritis.